Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

3710 - Adriamycin and Ifosfamide-based regimen as induction chemotherapy in desmoplastic small round cell tumors: results of a retrospective single-center study on 34 patients

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Cytotoxic Therapy

Tumour Site

Sarcoma

Presenters

Tarek Assi

Citation

Annals of Oncology (2018) 29 (suppl_8): viii576-viii595. 10.1093/annonc/mdy299

Authors

T.S. Assi1, A. Le Cesne1, E. Nassif1, A. Cavalcanti2, M. Faron2, T. Ibrahim1, C. Le Pechoux3, O. Mir1, J. Adam4, S. Dumont1, P. Terrier4, C. Honore2

Author affiliations

  • 1 Medical Oncology, Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 2 Surgery Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 3 Radiation oncology Department, Institut Gustave Roussy, 94800 - Villejuif/FR
  • 4 Pathology Department, Gustave Roussy, 94800 - Villejuif/FR
More

Resources

Abstract 3710

Background

Desmoplastic small round cell tumours (DSRCT) is a rare disease affecting predominantly children and young adults characterised by a specific translocation t(11:22)(p13;q12) which fuses the ESWR1 gene to the WT1 gene. DSRCT shares characteristics with other small-round blue cell cancers including Ewing's sarcoma. . The best induction chemotherapy (IC) is not yet defined. The aim of this study is to evaluate the role of Adriamycin and Ifosfamide (AI)-based regimen as IC in DSRCT.

Methods

All pts diagnosed in our tertiary care center with DSRCT treated with AI-based regimen as IC between 1991 and 2017 were included in this study. Demographic, clinical and long-term characteristics were obtained from the electronic medical records and retrospectively analyzed.

Results

34 pts were identified. With a median age of 25 yrs (range 18-56), 25 pts were male (74%). All pts had PS 0-1. 28 pts had symptoms (82%) with pain being the most common (n = 25). 14 pts (41%) had extra-peritoneal metastases (EPM) at diagnosis (liver mets (n = 14) associated with lung mets in 4 pts). Out of 34 pts, 26 pts (77%) received AI as IC. The remaining 8 pts had AI in combination to platinum agents (n = 4) or Etoposide (n = 4). Median number of cycles was 6±1 (range 3-9). Objective response and disease control rates were 71% and 91% respectively. Only 3 pts had progressive disease (PD) (9%). Dose reduction were noted in 2 pts with no treatment discontinuation. 41% had grade 3-4 toxicities. 7 pts (21%) developed febrile neutropenia. 17 pts (50%) underwent surgery (including 2 with EPM). Post-operative chemotherapy was given in 41 pts and radiotherapy in 21 pts. In pts who had surgery, local recurrence free survival was 10 months (95% CI: 7-12) while EPM-free survival was 13 months (95% CI: 7-19). Overall survival (OS) for pts without PD was 25.7 months (95% CI: 20.1-31.3). In pts who had surgery, OS was 28.3 months (95% CI: 13.6-43.1) while those who did not have surgery had an OS of 18.9 months (95% CI: 11.6-26.1).

Conclusions

AI-based regimen is a well-tolerated and active option with good response rate as an IC in DSRCT. Comparative data with currently used Ewing-type regimen are eagerly needed in the future.

Clinical trial identification

Legal entity responsible for the study

Institut Gustave Roussy.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.